ChiCTR-OCC-15006203 版本V1.1 版本创建时间2021/06/28 18:34:22 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR-OCC-15006203 

最近更新日期:

Date of Last Refreshed on:

2021-06-28 18:32:23 

注册时间:

Date of Registration:

2015-04-04 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

请上传伦理审批文件并填写伦理委员会相关信息。 前瞻、多中心、单组评价髂动脉分叉支架系统的安全性和有效性

Public title:

Evaluate the safety and efficacy of Iliac Bifurcation Stent Graft System: a prospective, multi-center single-arm clinical trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

前瞻、多中心、单组评价髂动脉分叉支架系统的安全性和有效性

Scientific title:

Evaluate the safety and efficacy of Iliac Bifurcation Stent Graft System: a prospective, multi-center single-arm clinical trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张祥满 

研究负责人:

郭伟 

Applicant:

Xiangman Zhang 

Study leader:

Wei Guo 

申请注册联系人电话:

Applicant telephone:

+86 13817024547

研究负责人电话:

Study leader's
telephone:

+86 010 66887329

申请注册联系人传真 :

Applicant Fax:

+86 755 86026251

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zhangxiangman@lifetechmed.com

研究负责人电子邮件:

Study leader's E-mail:

pla301dml@vip.sina.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

http://www.lifetechmed.com

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国广东省深圳市南山区高新技术产业园北区朗山二路赛霸科研楼

研究负责人通讯地址:

北京市海淀区复兴路28号

Applicant address:

Cybio Electronic Building, Langshan 2nd Street, North Area of High-tech Park, Nanshan District, Shenzhen, Guangdong, China

Study leader's address:

28 Fuxing Road, Haidian District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

518057

研究负责人邮政编码:

Study leader's postcode:

100853

申请人所在单位:

先健科技(深圳)有限公司

Applicant's institution:

Lifetech Scientific (Shenzhen) Co.Ltd.

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国人民解放军总医院

Primary sponsor:

The General Hospital of People’s Liberation Army

研究实施负责(组长)单位地址:

北京市海淀区复兴路28号

Primary sponsor's address:

28 Fuxing Road, Haidian District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

Country:

China

Province:

Guangdong

City:

单位(医院):

先健科技(深圳)有限公司

具体地址:

中国广东省深圳市南山区高新技术产业园北区朗山二路赛霸科研楼

Institution
hospital:

Lifetech Scientific (Shenzhen) Co.Ltd

Address:

Cybio Electronic Building,Langshan 2nd Street, North Area of High-tech Park, Nanshan District, Shenzhen, Guangdong,China

经费或物资来源:

先健科技(深圳)有限公司

Source(s) of funding:

Lifetech Scientific (Shenzhen) Co.Ltd.

研究疾病:

腹髂动脉瘤或髂总动脉瘤  

Target disease:

Abdominal iliac aneurysm or Common iliac artery aneurysms

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

治疗新技术临床试验 

Study phase:

New Treatment Measure Clinical Study

研究设计:

单臂 

Study design:

Single arm 

研究目的:

评价髂动脉分叉支架系统腔内治疗腹髂动脉瘤或髂总动脉瘤的安全性和有效性。  

Objectives of Study:

To evaluate the efficacy and safety of Iliac Bifurcation Stent Graft System in the treatment of abdominal iliac aneurysm or common iliac artery aneurysms.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1) 年龄≥18周岁。
2) 患者本人签署或法定代理人签署知情同意书。
3) 需要腔内重建髂内动脉的腹髂动脉瘤或髂总动脉瘤。
4)髂动脉解剖结构满足以下需求:
a. 髂外动脉锚定区长度≥15mm;
b. 髂外动脉锚定区直径在7-12mm之间;
c. 髂内动脉直径在6-10mm之间;
d. 髂内动脉锚定区长度≥10mm。
5) 患者至少有1年以上的生存预期。

Inclusion criteria

1. To be aged elder than 18 years old;
2. The patient or legal representative is able to understand and willing to provide written informed consent to participate in the trial;
3. The patient needs to reconstruct the abdominal iliac aneurysm or common iliac artery aneurysms;
4. Only the anatomical structure of iliac artery meeting the following requirements:
(1) The length of landing zone of the external iliac artery greater than 15mm;
(2) The diameter of landing zone of the external iliac artery is between 7-12mm;
(3) The diameter of the internal iliac artery is between 6-10mm;
(4) The length of landing zone of the internal iliac artery greater than 10mm;
5. The patient with at least 1 years survival expectancy.

排除标准:

1)患者小于18周岁。
2) 患者为怀孕或哺乳妇女。
3) 患者在入选前3个月之内有心肌梗死或脑卒中。
4) 患者存在结缔组织疾病、感染性动脉瘤及其他部位活动性感染。
5)患者的腹主动脉瘤破裂。
6) 患者有严重凝血功能障碍。
7)对支架材料或造影剂过敏者。
8)血管形态学上不适合行腔内修复术的患者,比如髂内动脉的严重狭窄、扩张、弯曲、硬化等。
9)动脉瘤腔内有严重附壁血栓影响分叉支架植入的患者。

Exclusion criteria:

1. The patient is younger than 18 years old;
2. Female patients in pregnancy or lactation;
3. The Patient had sufferred myocardial infarction or stroke within 3 months before screening;
4. The Patient suffers form connective tissue disease,infected aneurysms or other active infectionactivity;
5. Patients with ruptured abdominal aortic aneurysm;
6. The Patient has severe coagulation diaorders;
7. Patients with known allergy to the material of the stents and contrast agent;
8. From the view of the Vascular morphology,the patient doesn't suitable for endovascular repair,such as serious in the iliac artery stenosis, expansion, bending, hardening, etc.;
9. Aneurysm cavity with seriously mural thrombus that affect the implantation of Bifurcation stent.

研究实施时间:

Study execute time:

From 2014-09-30 00:00:00 To 2016-10-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2015-04-10 00:00:00 To 2016-04-10 00:00:00

干预措施:

Interventions:

组别:

单组

样本量:

64

Group:

single arm

Sample size:

干预措施:

介入治疗

干预措施代码:

Intervention:

interventional therapy

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

中国人民解放军总医院 

单位级别:

三级甲等 

Institution
hospital:

The General Hospital of Chinese People's Liberation Army

Level of the institution:

Tertiary A Hospitals

国家:

中国

省(直辖市):

上海市 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

复旦大学附属中山医院 

单位级别:

三级甲等 

Institution
hospital:

Zhongshan Hospital Fudan University

Level of the institution:

the Third-class A Hospitals

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京安贞医院 

单位级别:

三级甲等 

Institution
hospital:

Beijing Anzhen Hospital, Capital Medical University

Level of the institution:

the Third-class A Hospitals

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京协和医院 

单位级别:

三级甲等 

Institution
hospital:

Peking Union Medical College Hospital

Level of the institution:

the Third-class A Hospitals

国家:

中国

省(直辖市):

湖南 

市(区县):

 

Country:

China

Province:

Hunan

City:

单位(医院):

中南大学湘雅二医院 

单位级别:

三级甲等 

Institution
hospital:

The Second Xiangya Hospital of Central South University

Level of the institution:

the Third-class A Hospitals

国家:

中国

省(直辖市):

浙江 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

浙江大学医学院附属第一医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of Medical School of Zhejiang University

Level of the institution:

the Third-class A Hospitals

国家:

中国

省(直辖市):

四川 

市(区县):

 

Country:

China

Province:

Sichuan

City:

单位(医院):

四川大学华西医院 

单位级别:

三级甲等 

Institution
hospital:

West China Hospital of Sichuan University

Level of the institution:

the Third-class A Hospitals

国家:

中国

省(直辖市):

黑龙江 

市(区县):

 

Country:

China

Province:

Heilongjiang

City:

单位(医院):

哈尔滨医科大学附属第二医院 

单位级别:

三级甲等 

Institution
hospital:

The 2nd affiliated hospital of Harbin Medical University

Level of the institution:

the Third-class A Hospitals

国家:

中国

省(直辖市):

江苏 

市(区县):

 

Country:

China

Province:

Jiangsu

City:

单位(医院):

南京大学医学院附属鼓楼医院 

单位级别:

三级甲等 

Institution
hospital:

Nanjing Drum Tower Hospital

Level of the institution:

the Third-class A Hospitals

国家:

中国

省(直辖市):

辽宁 

市(区县):

 

Country:

China

Province:

Liaoning

City:

单位(医院):

中国医科大学附属第一医院 

单位级别:

三级甲等 

Institution
hospital:

The First Hospital of China Medical University

Level of the institution:

the Third-class A Hospitals

国家:

中国

省(直辖市):

天津 

市(区县):

 

Country:

China

Province:

Tianjin

City:

单位(医院):

天津大学总医院 

单位级别:

三级甲等 

Institution
hospital:

Tianjin Medical University General Hospital

Level of the institution:

the Third-class A Hospitals

国家:

中国

省(直辖市):

福建 

市(区县):

 

Country:

China

Province:

Fujian

City:

单位(医院):

福建医科大学附属协和医院 

单位级别:

三级甲等 

Institution
hospital:

Fujian Medical University Union Hospital

Level of the institution:

the Third-class A Hospitals

国家:

中国

省(直辖市):

江苏 

市(区县):

 

Country:

China

Province:

Jiangsu

City:

单位(医院):

苏州大学附属第二医院 

单位级别:

三级甲等 

Institution
hospital:

The Second Affiliated Hospital of Soochow University

Level of the institution:

the Third-class A Hospitals

国家:

中国

省(直辖市):

广东 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

中山大学附属第一医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital Sun Yat-sen University

Level of the institution:

the Third-class A Hospitals

国家:

中国

省(直辖市):

河南 

市(区县):

 

Country:

China

Province:

Henan

City:

单位(医院):

河南省人民医院 

单位级别:

三级甲等 

Institution
hospital:

Henan provincial people Hospita

Level of the institution:

the Third-class A Hospitals

国家:

中国

省(直辖市):

山东 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

山东省立医院 

单位级别:

三级甲等 

Institution
hospital:

Shandong Province Hospital

Level of the institution:

the Third-class A Hospitals

国家:

中国

省(直辖市):

山东 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

青岛大学附属医院 

单位级别:

三级甲等 

Institution
hospital:

The Affiliated Hospital of Qingdao University

Level of the institution:

the Third-class A Hospitals

国家:

中国

省(直辖市):

云南 

市(区县):

 

Country:

China

Province:

Yunnan

City:

单位(医院):

昆明医科大学第一附属医院 

单位级别:

三级甲等 

Institution
hospital:

First Affiliated Hospital of Kunming Medical University

Level of the institution:

the Third-class A Hospitals

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆医科大学附属第一医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of Chongqing Medical University

Level of the institution:

the Third-class A Hospitals

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京世纪坛医院 

单位级别:

三级甲等 

Institution
hospital:

Beijing Shijitan Hospital

Level of the institution:

the Third-class A Hospitals

国家:

中国

省(直辖市):

辽宁 

市(区县):

 

Country:

China

Province:

Liaoning

City:

单位(医院):

辽宁省人民医院 

单位级别:

三级甲等 

Institution
hospital:

The people's hospital of Liaoning Province

Level of the institution:

the Third-class A Hospitals

国家:

中国

省(直辖市):

辽宁 

市(区县):

 

Country:

China

Province:

Liaoning

City:

单位(医院):

大连医科大学附属第一医院 

单位级别:

三级甲等 

Institution
hospital:

The first affiliated hospital of dalian medical university

Level of the institution:

the Third-class A Hospitals

国家:

中国

省(直辖市):

河北 

市(区县):

 

Country:

China

Province:

Hebei

City:

单位(医院):

河北医科大学附属第二医院 

单位级别:

三级甲等 

Institution
hospital:

The Second Hospital of Hebei Medical University

Level of the institution:

the Third-class A Hospitals

国家:

中国

省(直辖市):

江苏 

市(区县):

 

Country:

China

Province:

Jiangsu

City:

单位(医院):

江苏省人民医院 

单位级别:

三级甲等 

Institution
hospital:

Jiangsu Province Hospital

Level of the institution:

the Third-class A Hospitals

国家:

中国

省(直辖市):

云南 

市(区县):

 

Country:

China

Province:

Yunnan

City:

单位(医院):

成都军区昆明总医院 

单位级别:

三级甲等 

Institution
hospital:

Kunming General Hospital of Chengdu Military Area

Level of the institution:

the Third-class A Hospitals

国家:

中国

省(直辖市):

黑龙江 

市(区县):

 

Country:

China

Province:

Heilongjiang

City:

单位(医院):

哈尔滨医科大学附属第一医院 

单位级别:

三级甲等 

Institution
hospital:

First Affiliated Hospital of Harbin Medical University

Level of the institution:

the Third-class A Hospitals

测量指标:

Outcomes:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

髂内动脉通畅率

组织:

Sample Name:

The patency rate of internal iliac artery

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 95 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

单组

Randomization Procedure (please state who generates the random number sequence and by what method):

single arm

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

先健科技(深圳)有限公司

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Lifetech Scientific(Shenzhen)Co.Ltd.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

北京大学临床研究所

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Peking University Clinical Research Institute

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2015-04-07 11:14:37